Form 4: Abbott Laboratories Director Receives Equity Grant

Director Darren W. McDew was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program.

Summary

• Director Darren W. McDew acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
• The grant was issued under the Abbott Laboratories 2026 Incentive Stock Program.
• The RSUs are payable on a one-to-one basis in common shares upon separation from service, death, or a change in control.
• Following this transaction, the director's total beneficial ownership is 12,678 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard incentive structure for corporate governance.

Negatives

• None identified; this is a routine compensatory disclosure.

Risks

• Value of the equity grant is subject to future fluctuations in Abbott Laboratories' common stock price.

Future Outlook

The RSUs will vest and be paid out upon the director's separation from service, death, or a change in control of the company.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice among large-cap healthcare and pharmaceutical companies to ensure long-term alignment with corporate performance.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with governance practices at peer companies like Medtronic, Danaher, and Thermo Fisher Scientific.
• The one-to-one conversion ratio is standard for equity incentive plans in the S&P 500.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensatory grant.

Next Steps

• No further action required by the company; the director will hold these units until a triggering event occurs.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Director Compensation, Equity Grant, Insider Ownership